Morgan Stanley Lowers PT on Marvell (MRVL) Stock, Keeps Equal Weight Rating

On May 27, Morgan Stanley lowered its price target on Marvell Technology, Inc. (NASDAQ:MRVL) from $90 to $70, keeping an Equal Weight rating on the shares.

Joseph Moore from Morgan Stanley downgraded the price target on MRVL after the company revised its revenue guidance for the upcoming Q1 FY2026 report on May 29. Marvell Technology reiterated its revenue guidance, lowering the range to $1.85 billion +/- 2%, compared to the previous guidance of +/- 5% growth.

Moore sees this pre-announcement ahead of the earnings call as “somewhat disappointing” considering the ongoing positivity from the Trainium supply chain, strength in optical, and a projected rebound in conventional networking/communications infrastructure.

Marvell’s mid-point quarterly guidance update comes amidst a challenging macroeconomic climate, which has led the company to postpone its Investor Day, initially scheduled for June 10, to an undetermined date in 2026. However, the company remains positive about its development in the custom AI silicon sector and has scheduled a webinar to discuss the technical areas in the sector. The webinar conference will be held on June 17, from 10:00 am to 12:00 pm PT.

Marvell Technology, Inc. (NASDAQ:MRVL) is a leading supplier of data infrastructure semiconductor solutions, ranging from the data center core to the network edge. The company is engaged in the design, development, and marketing of integrated circuits (ICs). Marvell’s product solutions serve five end markets, including data center, carrier infrastructure, enterprise networking, consumer, and automotive.

While we acknowledge the potential of MRVL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRVL and that has 100x upside potential, check out our report about this cheapest AI stock.

Read Next: 30 Best Stocks to Buy Now According to Billionaires and 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying.

Disclosure. None.